glp-1 receptor agonists for individualized treatment of type 2 diabetes mellitus GLP-1 Receptor Agonists | New
Description
Pharmacol Rev 2016;68:9541013.ArticlePubMedPMC 30
Additionally, an obstacle to drug treatment for obesity is that the drug is perceived as ineffective because the patient gains weight again when the drug is stopped
The other has to do with reducing inflammation
Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling
Most of the trials were conducted in middle- and high-income countries, with little or no representation from regions such as Africa, Central America, and Southeast Asia
These studies cannot be compared directly head to head, due to differences in study design and timepoints at which weight was measured
